ReviewImmunity, inflammation and disease2025
Research Progress of Annexin A1 and Its Derived Peptides in the Diagnosis and Treatment of Circulatory Diseases.
Review in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAnnexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein, plays a critical role in regulating inflammation, apoptosis, immune responses, and vascular remodeling. It is increasingly recognized for its potential as a therapeutic target and diagnostic biomarker in various circulatory diseases, including sepsis, hypertension, coronary heart disease, myocardial ischemia-reperfusion injury, heart failure, and cerebrovascular disorders. ANXA1 and its derived peptides exert protective effects by modulating key signaling pathways and cellular processes involved in disease pathogenesis.
aimThis review summarizes the current research progress on ANXA1 and its derived peptides in the diagnosis and treatment of circulatory diseases, highlighting their mechanisms of action and therapeutic potential.
methodA comprehensive literature search was conducted using PubMed, Web of Science, and other relevant databases. Articles published up to 2024 were included, with a focus on experimental studies, clinical reports, and reviews addressing the role of ANXA1 in circulatory diseases. Key themes included anti-inflammatory mechanisms, apoptosis regulation, immune modulation, and vascular protection.
resultANXA1 and its mimetic peptides like Ac2-26, ANXA1sp, RTP-026 and so on demonstrate significant protective effects across multiple circulatory diseases. They attenuate inflammation, oxidative stress, apoptosis, and ferroptosis, while promoting mitochondrial biosynthesis and immune regulation. These effects are mediated through receptors such as FPR2/ALX and pathways involving SIRT3, PI3K/Akt, and AMPK/mTOR. However, the role of ANXA1 can be context-dependent, exhibiting both protective and detrimental effects in specific conditions such as gestational hypertension and transient ischemic attack.
conclusionANXA1 represents a promising diagnostic biomarker and therapeutic target for circulatory diseases. Further research is needed to elucidate its complex regulatory networks and validate its clinical applicability through multi-omics approaches and large-scale trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.